In September 2026, UNODC reported that five new psychoactive substances would be considered for critical review by the WHO Expert Committee on Drug Dependence. The list included emerging synthetic opioids and designer benzodiazepines.
NPS are psychoactive substances that emerge or re-emerge in markets and can change faster than regulation and laboratory surveillance. For users, the major problem is uncertainty: composition, potency, and health effects may be difficult to know. Street names, packaging, or product appearance do not guarantee what is actually inside.
Practical takeaways:
-
Do not rely on street names or appearance to identify a substance.
-
New does not mean safer or weaker.
-
Use official public-health alerts rather than rumors or forums for risk information.
0 comments